Semaglutide’s heart benefits may extend beyond weight loss
Semaglutide is known to reduce the risk of serious heart disease. However, a new study published in the…
Semaglutide extended lifespan in older female mice, but that was not the only finding
A late-life experiment reveals how a widely used metabolic drug reshapes age-related physiology and molecular pathways, with effects…
Ten-million-person study links semaglutide to lower COVID-19 mortality
After accounting for major health differences between semaglutide users and non-users, researchers identified a striking mortality association that…
Nearly one in 10 Britons use or want weight-loss medication
A nationally representative survey estimates that millions of adults in Great Britain have already used GLP-1-based weight-loss medicines…
New oral drug shows promise for chronic heart failure treatment
An early clinical study shows that a new oral drug is safe and well-tolerated in patients with chronic…
GLP-1 medicines may cut clot-related risks in chronically inflamed patients
A large real-world analysis suggests GLP-1 receptor agonists may offer clot-related and survival benefits in a chronically inflamed,…
Could GLP-1 drugs help prevent breast cancer? New study points to a possible link
A major breast imaging study links GLP-1 agonists to lower breast cancer incidence, raising hopes for a new…
Exercise remains essential alongside GLP-1 obesity treatments
As GLP-1 receptor agonists reshape obesity treatment, a new medical perspective published in the Journal of the American…
GLP-1 medications show mixed effects on body contouring outcomes
For patients undergoing body contouring surgery to remove excess abdominal skin after massive weight loss, use of GLP-1 weight-loss medications may have mixed effects…
Study finds GLP-1 medicines cut fat while preserving muscle function
A new study in mice and humans suggests GLP-1 medicines drive weight loss primarily by reducing fat, while…
Combining healthy lifestyle and GLP-1 therapy reduces heart risks in diabetes
Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they…
Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity
Can combining two gut hormone pathways unlock better obesity treatments? In the first human trial of dapiglutide, researchers…